[ad_1]
Young people at very high risk of psychosis appeared to have cognitive deficits, according to the results of the study published in JAMA Psychiatry .
However, those whose high-risk status re-emerged seemed to be recovering cognitively, according to the results.
"Meta-analytic data indicate that cognitive deficits are present in individuals at very high risk of psychosis.There is a 35% probability that the presence of symptoms – functional or cognitive manifestations – in persons with high risk and seeking care precedes psychosis " Max Lam, PhD, of the research division of the Health Institute in Singapore, and his colleagues wrote." However, systematic evidence is rare for longitudinal cognitive trajectories in individuals with [ultra-high risk] for psychosis. "
Researchers assessed the longitudinal profiles of cognition in young adults at very high risk of psychosis, healthy controls, and control of psychosis. study of the link between cognition and functioning using a prospective multi-group model in the longitudinal study of at-risk youth in Sing
Every 6 months for 2 years or until psychosis is converted into assessments to measure cognitive neuropsychological, perceptual and social tasks; they also administered semi-structured interviews and structured clinical interview for DSM-IV Axis I D Isorders . They grouped those at risk as converters or non-converters and shippers or non-shippers. Specifically, they ranked those who had a very high risk of psychosis initially, but who no longer met the criteria of extremely high risk at 2 years as offenders and those who met the criteria at the final assessment or who were As a result, the researchers evaluated 173 young adults at very high risk of psychosis and 384 healthy controls aged 14 to 29, but only 383 healthy controls and 122 people at risk for psychosis are remained after 2 years of follow-up. Initially, cognitive deficits were correlated with subsequent conversion to psychosis (OR = 1.66, 95% CI, 1.08-2.83, P = 0.04), and non-remission. ultra-high risk status (OR = 1.67, CI, 1.09-2.95, P = 0.04).
Lam and his colleagues obtained five cognitive components from the analysis of the main components – social cognition, attention, verbal fluency, general cognitive function and perception.
In general, cognitive function, they found that the structure of the longitudinal component has changed ( P = 0.01). There was also a group-by-time interaction on general cognitive function ( P <.001) and perception ( P <.001). In addition, researchers reported that changes in attention ( P = 0.02) and general cognitive function ( P = 0.01) accounted for the changes in in social and professional functioning
. ] "Although it acts mainly in one feature, cognitive architecture shows subtle changes over time in non-recurring individuals to [ultra-high risk] for psychosis", write the researchers. "These changes in cognitive architecture are associated with functional outcomes and may herald a conversion to psychosis and cognitive architecture similar to schizophrenia."
More research in the treatment of cognitive deficits in patients on the spectrum of schizophrenia, Harvey, PhD, of the Miller School of Medicine, University of Miami, wrote in an editorial of 39; accompaniment.
"If we want to observe the cognitive worsening that seems to increase the risk of persistent symptoms, we will have to look earlier, perhaps before the behavioral changes associated with the prodrome," he writes. "Given the challenges of treating cognitive deficits and the limited success of pharmacological approaches, the longitudinal correlations between cognition and daily functioning also demonstrate the true clinical relevance of cognitive impairment treatments. " – by Savannah Demko
Disclosure: Lam does not report any relevant financial disclosure.Please consult the complete study for relevant financial information of other authors. reports consulting fees or travel reimbursements from Allergan, Akili, Biogen, Boehringer Ingelheim, Forum Pharma, Genentech (Roche Pharma), Intracellular Therapies, Lundbeck Pharma, of Minerva Pharma, Otsuka America, Sanofi Pharma and Sunovion Pharma, Takeda Pharma and Teva, royalties from the brief assessment of cognition in schizophrenia and grants from Takeda and Stanley Medical Research Foundation
Young people at very high risk for psychosis appeared to have cognitive deficits, according to a study published in JAMA Psychiatry Revealed.
However, those whose status at high risk reappeared seemed to recover cognitively, according to the results.
"Meta-analytic data indicate that cognitive deficits are present in individuals at very high risk of psychosis.There is a 35% probability that the presence of symptoms – functional or cognitive manifestations – in persons with high risk and seeking care precedes psychosis " Max Lam, PhD, of the research division of the Health Institute in Singapore, and his colleagues wrote." However, systematic evidence is rare for longitudinal cognitive trajectories in individuals with [ultra-high risk] for psychosis. "
Researchers assessed the longitudinal profiles of cognition in young adults at very high risk of psychosis, healthy controls, and control of psychosis. study of the link between cognition and functioning using a prospective multi-group model in the longitudinal study of at-risk youth in Sing
Every 6 months for 2 years or until psychosis is converted into assessments to measure cognitive neuropsychological, perceptual and social tasks; they also administered semi-structured interviews and structured clinical interview for DSM-IV Axis I D Isorders . They grouped those at risk as converters or non-converters and shippers or non-shippers. Specifically, they ranked those who had a very high risk of psychosis initially, but who no longer met the criteria of extremely high risk at 2 years as offenders and those who met the criteria at the final assessment or who were As a result, the researchers evaluated 173 young adults at very high risk of psychosis and 384 healthy controls aged 14 to 29, but only 383 healthy controls and 122 people at risk for psychosis are remained after 2 years of follow-up. Initially, cognitive deficits were correlated with subsequent conversion to psychosis (OR = 1.66, 95% CI, 1.08-2.83, P = 0.04), and non-remission. ultra-high risk status (OR = 1.67, CI, 1.09-2.95, P = 0.04).
Lam and his colleagues obtained five cognitive components from the analysis of the main components – social cognition, attention, verbal fluency, general cognitive function and perception.
In general, cognitive function, they found that the structure of the longitudinal component has changed ( P = 0.01). There was also a group-by-time interaction on general cognitive function ( P <.001) and perception ( P <.001). In addition, researchers reported that changes in attention ( P = 0.02) and general cognitive function ( P = 0.01) accounted for the changes in in social and professional functioning. [19659002] PAGE BREAK
"Although it mainly acts in one stroke, cognitive architecture shows subtle changes over time in non-recurring individuals at [ultra-high risk] for psychosis, "the researchers write. "These changes in cognitive architecture are associated with functional outcomes and may herald a conversion to psychosis and cognitive architecture similar to schizophrenia."
More research in the treatment of cognitive deficits in patients on the spectrum of schizophrenia, Harvey, PhD, of the Miller School of Medicine, University of Miami, wrote in an editorial of 39; accompaniment.
"If we want to observe the cognitive worsening that seems to increase the risk of persistent symptoms, we will have to look earlier, perhaps before the behavioral changes associated with the prodrome," he writes. "Given the challenges of treating cognitive deficits and the limited success of pharmacological approaches, the longitudinal correlations between cognition and daily functioning also demonstrate the true clinical relevance of cognitive impairment treatments. " – by Savannah Demko
Disclosure: Lam does not report any relevant financial disclosure.Please consult the complete study for relevant financial information of other authors. reports consulting fees or travel reimbursements from Allergan, Akili, Biogen, Boehringer Ingelheim, Forum Pharma, Genentech (Roche Pharma), Intracellular Therapies, Lundbeck Pharma, of Minerva Pharma, Otsuka America, Sanofi Pharma and Sunovion Pharma, Takeda Pharma and Teva, royalties from the brief assessment of cognition in schizophrenia and grants from Takeda and Stanley Medical Research Foundation.
[ad_2]
Source link
